Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950123-08-003570
Filing Date
2008-03-31
Accepted
2008-03-31 11:51:57
Documents
6
Period of Report
2007-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K y52254e10vk.htm 10-K 647537
2 EX-23.1: CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM y52254exv23w1.htm EX-23.1 1647
3 EX-31.1: CERTIFICATION y52254exv31w1.htm EX-31.1 8537
4 EX-31.2: CERTIFICATION y52254exv31w2.htm EX-31.2 8730
5 EX-32.1: CERTIFICATION y52254exv32w1.htm EX-32.1 3512
6 EX-32.2: CERTIFICATION y52254exv32w2.htm EX-32.2 3400
  Complete submission text file 0000950123-08-003570.txt   674795
Mailing Address 555 MADISON AVENUE, 25TH FLOOR NEW YORK NY 10022
Business Address 555 MADISON AVENUE, 25TH FLOOR NEW YORK NY 10022 212-716-1810
Innovive Pharmaceuticals, Inc. (Filer) CIK: 0001337223 (see all company filings)

EIN.: 743123261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-51534 | Film No.: 08722483
SIC: 2836 Biological Products, (No Diagnostic Substances)